Albion Financial Group UT Has $264,000 Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Albion Financial Group UT boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 5.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,974 shares of the medical instruments supplier’s stock after buying an additional 212 shares during the period. Albion Financial Group UT’s holdings in LeMaitre Vascular were worth $264,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in LMAT. Exchange Traded Concepts LLC increased its position in shares of LeMaitre Vascular by 0.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock worth $1,343,000 after acquiring an additional 187 shares in the last quarter. Riverwater Partners LLC raised its stake in shares of LeMaitre Vascular by 2.5% in the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock worth $466,000 after purchasing an additional 198 shares during the last quarter. Personal CFO Solutions LLC raised its stake in shares of LeMaitre Vascular by 6.4% in the fourth quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock worth $316,000 after purchasing an additional 336 shares during the last quarter. SRS Capital Advisors Inc. lifted its holdings in shares of LeMaitre Vascular by 325.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 524 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of LeMaitre Vascular by 4.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 11,858 shares of the medical instruments supplier’s stock valued at $673,000 after buying an additional 555 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the completion of the transaction, the chief executive officer now owns 2,079,128 shares of the company’s stock, valued at $156,558,338.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO George W. Lemaitre sold 8,000 shares of the stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $75.30, for a total value of $602,400.00. Following the transaction, the chief executive officer now owns 2,079,128 shares of the company’s stock, valued at approximately $156,558,338.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director David B. Roberts sold 5,025 shares of LeMaitre Vascular stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.62, for a total transaction of $379,990.50. Following the sale, the director now directly owns 14,114 shares of the company’s stock, valued at $1,067,300.68. The disclosure for this sale can be found here. Insiders have sold a total of 87,431 shares of company stock valued at $6,627,520 in the last 90 days. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $81.30 on Thursday. The business has a fifty day moving average price of $77.49 and a 200-day moving average price of $67.18. The firm has a market capitalization of $1.83 billion, a P/E ratio of 53.84, a PEG ratio of 2.47 and a beta of 0.89. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $84.15.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. The company had revenue of $53.48 million during the quarter, compared to analyst estimates of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. LeMaitre Vascular’s revenue was up 13.6% compared to the same quarter last year. During the same period last year, the business earned $0.27 earnings per share. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 30th. Investors of record on Thursday, May 16th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend was Wednesday, May 15th. LeMaitre Vascular’s payout ratio is 42.38%.

Analyst Ratings Changes

LMAT has been the topic of several analyst reports. JMP Securities boosted their price target on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a report on Friday, May 3rd. Roth Mkm reissued a “buy” rating and issued a $100.00 price target on shares of LeMaitre Vascular in a report on Friday, May 31st. Barrington Research raised their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, June 22nd. Finally, Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $77.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.